AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 212.02B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.53 |
| Forward PE | 18.07 |
| Dividend | 2.39 (1.76%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 10,404,650 |
| Average Volume | 2,298,309 |
| Open | 13,574 |
| Previous Close | 13,548 |
| Day's Range | 13,508 - 15,474 |
| 52-Week Range | 9,574 - 15,474 |
| Beta | 0.17 |
| RSI | 56.84 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
AstraZeneca (AZN) Among Companies Prepping Price Reductions
AstraZeneca (AZN) Among Companies Prepping Price Reductions
Watch live: Trump to deliver announcement on drug pricing
President Trump on Friday afternoon will make an announcement related to lowering drug prices — an effort he has leaned into ahead of the 2026 midterm elections. In recent months, Trump has struck dea...
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
AstraZeneca's Andexxa being removed from market over safety concerns
AstraZeneca’s Andexxa will be withdrawn due to FDA concerns over serious thromboembolic risks. Read more here.
AstraZeneca: Mispriced Growth Following The Oncology Segment Success
AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.
AstraZeneca (AZN) Expands Actinium-225 Supply Agreement with Niowave
AstraZeneca (AZN) Expands Actinium-225 Supply Agreement with Niowave
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still at an earl...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Compugen rises on royalty deal with AstraZeneca
Compugen (CGEN) stock rises as the company secures $65M upfront from AstraZeneca (AZN) by monetizing part of its cancer drug royalties. Read more here.
AstraZeneca (AZN) and Compugen Partner to Monetize Royalties on Novel Therapy
AstraZeneca (AZN) and Compugen Partner to Monetize Royalties on Novel Therapy
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
AstraZeneca (AZN) Receives EU Approval for Saphnelo Self-Administration
AstraZeneca (AZN) Receives EU Approval for Saphnelo Self-Administration
AstraZeneca Announces Approval Of Saphnelo In The EU
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) said its Saphnelo - anifrolumab - has been approved in the European Union for subcutaneous self-administration as a pre-filled pen for adult pa...
AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer
(RTTNews) - AstraZeneca and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, has received approval in the United States for the first-line treatment of adult...
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Astrazeneca (AZN) closed the most recent trading day at $91.56, moving +1.93% from the previous trading session.
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA Approval
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA Approval
AstraZeneca (AZN) Gains FDA Approval for Breast Cancer Treatment
AstraZeneca (AZN) Gains FDA Approval for Breast Cancer Treatment
AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of ...
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Therapy
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cancer Therapy